{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:40:52Z","timestamp":1780051252231,"version":"3.53.1"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Natural Sciences and Engineering Research Council (NSERC) of Canada","award":["3617"],"award-info":[{"award-number":["3617"]}]},{"name":"CONACyT of Mexico to CGMM","award":["238340"],"award-info":[{"award-number":["238340"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Growth Hormone & IGF Research"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.ghir.2016.03.004","type":"journal-article","created":{"date-parts":[[2016,3,28]],"date-time":"2016-03-28T12:00:56Z","timestamp":1459166456000},"page":"28-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Growth hormone and ocular dysfunction: Endocrine, paracrine or autocrine etiologies?"],"prefix":"10.1016","volume":"29","author":[{"given":"Steve","family":"Harvey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos G.","family":"Martinez-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ghir.2016.03.004_bb0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000262529","article-title":"Role of the growth hormone\/insulin-like growth factor 1 axis in neurogenesis","volume":"17","author":"Aberg","year":"2010","journal-title":"Endocr. Dev."},{"key":"10.1016\/j.ghir.2016.03.004_bb0010","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ghir.2009.12.003","article-title":"Peripheral growth hormone induces cell proliferation in the intact adult rat brain","volume":"20","author":"Aberg","year":"2010","journal-title":"Growth Hormon. IGF Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1677\/JOE-08-0495","article-title":"Peripheral administration of GH induces cell proliferation in the brain of adult hypophysectomized rats","volume":"201","author":"Aberg","year":"2009","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.dsx.2014.09.011","article-title":"Diabetic retinopathy\u2013biomolecules and multiple pathophysiology","volume":"9","author":"Ahsan","year":"2015","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.ghir.2016.03.004_bb0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2337\/diacare.17.6.531","article-title":"The role of growth hormone in the development of diabetic retinopathy","volume":"17","author":"Alzaid","year":"1994","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ghir.2016.03.004_bb0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.neures.2013.03.014","article-title":"Role of growth hormone (GH) in the treatment on neural diseases: from neuroprotection to neural repair","volume":"76","author":"Arce","year":"2013","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0035","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4103\/2230-8210.131207","article-title":"Diabetic retinopathy in acromegaly","volume":"18","author":"Azzoug","year":"2014","journal-title":"Indian J. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2016.03.004_bb0040","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1001\/archinte.1981.00340130069016","article-title":"Rarity of diabetic retinopathy in patients with acromegaly","volume":"141","author":"Ballintine","year":"1981","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ghir.2016.03.004_bb0045","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1210\/en.2008-1242","article-title":"Growth hormone promotes axon growth in the developing nervous system","volume":"150","author":"Baudet","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.ghir.2016.03.004_bb0050","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/pmic.200700952","article-title":"Growth hormone action in the developing neural retina: a proteomic analysis","volume":"8","author":"Baudet","year":"2008","journal-title":"Proteomics"},{"key":"10.1016\/j.ghir.2016.03.004_bb0055","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1210\/en.2003-0651","article-title":"Retinal growth hormone in the chick embryo","volume":"144","author":"Baudet","year":"2003","journal-title":"Endocrinology"},{"key":"10.1016\/j.ghir.2016.03.004_bb0060","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/S0161-6420(01)00853-3","article-title":"The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy","volume":"108","author":"Beck","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ghir.2016.03.004_bb0065","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1210\/jcem.85.2.6403","article-title":"Growth hormone replacement therapy is not associated with retinal changes","volume":"85","author":"Blank","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2016.03.004_bb0070","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1002\/stem.120","article-title":"Exercise increases neural stem cell number in a growth hormone-dependent manner, augmenting the regenerative response in aged mice","volume":"27","author":"Blackmore","year":"2009","journal-title":"Stem Cells"},{"key":"10.1016\/j.ghir.2016.03.004_bb0075","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/srep00250","article-title":"Growth hormone responsive neural precursor cells reside within the adult mammalian brain","volume":"2","author":"Blackmore","year":"2012","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ghir.2016.03.004_bb0080","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1055\/s-2001-15282","article-title":"Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy","volume":"33","author":"Boehm","year":"2001","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0085","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1055\/s-2001-19133","article-title":"Microvascular permeability is increased in both types of diabetes and correlates differentially with serum levels of insulin-like growth factor I (IGF-I) and vascular endothelial growth factor (VEGF)","volume":"33","author":"Brausewetter","year":"2001","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0090","first-page":"1001","article-title":"[Trial treatment of diabetic retinopathy by inhibition of pituitary somatotropin secretion with MAP]","volume":"66","author":"Bruni","year":"1975","journal-title":"Minerva Med."},{"key":"10.1016\/j.ghir.2016.03.004_bb0095","first-page":"154","article-title":"Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for growth hormone excess and for hyperglycemia","volume":"35","author":"Cambuli","year":"2012","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.ghir.2016.03.004_bb0100","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.2337\/dc07-0332","article-title":"Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration","volume":"30","author":"Carrasco","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ghir.2016.03.004_bb0105","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/S0161-6420(02)01270-8","article-title":"Effect of a growth hormone receptor antagonist on proliferative diabetic retinopathy","volume":"109","author":"Chantelau","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ghir.2016.03.004_bb0110","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ghir.2009.05.001","article-title":"Growth hormone receptor immunoreactivity is increased in the subventricular zone of juvenile rat brain after focal ischemia: a potential role for growth hormone in injury-induced neurogenesis","volume":"19","author":"Christophidis","year":"2009","journal-title":"Growth Hormon. IGF Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0115","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S0026-0495(99)90261-5","article-title":"Octreotide (somatostatin analog) treatment reduces endothelial cell dysfunction in patients with diabetes mellitus","volume":"48","author":"Clemens","year":"1999","journal-title":"Metabolism"},{"key":"10.1016\/j.ghir.2016.03.004_bb0120","first-page":"1251","article-title":"Resistance of growth hormone secretion to somatostatin in men with type I diabetes","volume":"40","author":"Cohen","year":"1991"},{"key":"10.1016\/j.ghir.2016.03.004_bb0125","first-page":"826","article-title":"Altered platelet function in diabetes mellitus","volume":"25","author":"Colwell","year":"1976","journal-title":"Diabetes"},{"key":"10.1016\/j.ghir.2016.03.004_bb0130","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2174\/1566524043360375","article-title":"Antisense strategies","volume":"4","author":"Crooke","year":"2004","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.ghir.2016.03.004_bb0135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pharmthera.2004.02.002","article-title":"Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis","volume":"102","author":"Dasgupta","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ghir.2016.03.004_bb0140","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1055\/s-2001-15286","article-title":"The therapeutic problem of proliferative diabetic retinopathy: targeting somatostatin receptors","volume":"33","author":"Davis","year":"2001","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1464-5491.1989.tb02096.x","article-title":"Somatostatin analogues in diabetes mellitus","volume":"6","author":"Davies","year":"1989","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ghir.2016.03.004_bb0150","doi-asserted-by":"crossref","first-page":"30470","DOI":"10.3390\/ijms161226244","article-title":"Brain recovery after a plane crash: treatment with growth hormone (GH) and neurorehabilitation: a case report","volume":"16","author":"Devesa","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ghir.2016.03.004_bb0155","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1471-2202-15-100","article-title":"Growth hormone pathways signaling for cell proliferation and survival in hippocampal neural precursors from postnatal mice","volume":"15","author":"Devesa","year":"2014","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.ghir.2016.03.004_bb0160","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.medcli.2009.10.017","article-title":"Growth hormone revisited","volume":"135","author":"Devesa","year":"2010","journal-title":"Med. Clin. (Barc.)"},{"key":"10.1016\/j.ghir.2016.03.004_bb0165","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2337\/diacare.23.11.1694","article-title":"von Willebrand factor and retinal circulation in early-stage retinopathy of type 1 diabetes","volume":"23","author":"Feng","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ghir.2016.03.004_bb0170","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/bjo.2003.034918","article-title":"Shedding light on a new eye protein","volume":"88","author":"Forrester","year":"2004","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0175","first-page":"473","article-title":"Nocturnal use of perenzepine in young insulin dependent diabetics. Results of a 6-month treatment period","volume":"37","author":"Francisco","year":"1992","journal-title":"An. Esp. Pediatr."},{"key":"10.1016\/j.ghir.2016.03.004_bb0180","first-page":"482","article-title":"Pituitary ablation by yttrium-90 implants for diabetic retinopathy","volume":"11","author":"Fraser","year":"1962","journal-title":"Diabetes"},{"issue":"Suppl. 1","key":"10.1016\/j.ghir.2016.03.004_bb0185","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1055\/s-2005-861362","article-title":"The growth hormone hypothesis \u2014 2005 revision","volume":"37","author":"Frystyk","year":"2005","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0190","first-page":"114","article-title":"The role of modulation of GH\/IGF-I axis in the development of diabetic proliferative retinopathy","volume":"26","author":"Genovese","year":"2003","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.ghir.2016.03.004_bb0195","first-page":"752","article-title":"Pegvisomant. Pharmacia","volume":"3","author":"Goffin","year":"2002","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.ghir.2016.03.004_bb0200","first-page":"87","article-title":"Administration of antisomatotropin serum in diabetes mellitus","volume":"77","author":"Goth","year":"1981","journal-title":"Endocrinology"},{"key":"10.1016\/j.ghir.2016.03.004_bb0205","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1358\/dot.2002.38.11.820138","article-title":"Somatostatin analogues as drug therapies for retinopathies","volume":"38","author":"Grant","year":"2002","journal-title":"Drugs Today (Barc.)"},{"key":"10.1016\/j.ghir.2016.03.004_bb0210","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2337\/diacare.23.4.504","article-title":"The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study","volume":"23","author":"Grant","year":"2000","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ghir.2016.03.004_bb0215","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000308886","article-title":"GH secretion in open-angle glaucoma","volume":"179","author":"Greco","year":"1979","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ghir.2016.03.004_bb0220","first-page":"2902","article-title":"[Secretion of GH and diabetic retinopathy]","volume":"67","author":"Greco","year":"1976","journal-title":"Minerva Med."},{"key":"10.1016\/j.ghir.2016.03.004_bb0225","first-page":"456","article-title":"Tractional force generation by porcine Muller cells. Development and differential stimulation by growth factors","volume":"38","author":"Guidry","year":"1997","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ghir.2016.03.004_bb0230","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1167\/iovs.02-0046","article-title":"Tractional force generation by human muller cells: growth factor responsiveness and integrin receptor involvement","volume":"44","author":"Guidry","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ghir.2016.03.004_bb0235","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.2337\/diabetes.53.9.2428","article-title":"Changes in IGF activities in human diabetic vitreous","volume":"53","author":"Guidry","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.ghir.2016.03.004_bb0240","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.2337\/diabetes.51.10.3107","article-title":"Pericytes and the pathogenesis of diabetic retinopathy","volume":"51","author":"Hammes","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.ghir.2016.03.004_bb0245","first-page":"2627","article-title":"Full remission of growth hormone (GH)-induced retinopathy after GH treatment discontinuation: long-term follow-up","volume":"85","author":"Hansen","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2016.03.004_bb0250","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ygcen.2014.11.004","article-title":"Autocrine\/paracrine roles of extrapituitary growth hormone and prolactin in health and disease: an overview","volume":"220","author":"Harvey","year":"2015","journal-title":"Gen. Comp. Endocrinol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0255","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12020-011-9557-z","article-title":"Extrapituitary production of anterior pituitary hormones: an overview","volume":"41","author":"Harvey","year":"2012","journal-title":"Endocrine"},{"key":"10.1016\/j.ghir.2016.03.004_bb0260","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ygcen.2012.01.021","article-title":"Release of retinal growth hormone in the chick embryo: local regulation?","volume":"176","author":"Harvey","year":"2012","journal-title":"Gen. Comp. Endocrinol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0265","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12020-010-9403-8","article-title":"Extrapituitary growth hormone","volume":"38","author":"Harvey","year":"2010","journal-title":"Endocrine"},{"key":"10.1016\/j.ghir.2016.03.004_bb0270","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.neulet.2009.03.073","article-title":"Growth hormone is present in the human retina and vitreous fluid","volume":"455","author":"Harvey","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ghir.2016.03.004_bb0275","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1749-6632.2008.03641.x","article-title":"Growth hormone-induced neuroprotection in the neural retina during chick embryogenesis","volume":"1163","author":"Harvey","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ghir.2016.03.004_bb0280","first-page":"510","article-title":"Growth hormone and developmental ocular function: clinical and basic studies","volume":"5","author":"Harvey","year":"2007","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.ghir.2016.03.004_bb0285","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ygcen.2006.12.024","article-title":"Growth hormone in the visual system: comparative endocrinology","volume":"153","author":"Harvey","year":"2007","journal-title":"Gen. Comp. Endocrinol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0290","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/1056-8727(93)90018-T","article-title":"Is growth hormone associated with diabetic retinopathy?","volume":"7","author":"Hattori","year":"1993","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.ghir.2016.03.004_bb0295","first-page":"795","article-title":"Reduced retinal vascularization in children with growth hormone deficiency","volume":"84","author":"Hellstrom","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2016.03.004_bb0300","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1006\/exer.2001.1147","article-title":"Somatostatin analogs inhibit neonatal retinal neovascularization","volume":"74","author":"Higgins","year":"2002","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0305","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0008-6363(96)00063-6","article-title":"Pericytes in the microvasculature","volume":"32","author":"Hirschi","year":"1996","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0310","first-page":"50","article-title":"Types of diabetic retinopathy and treatment","volume":"25","author":"Hollows","year":"1973","journal-title":"Trans. Ophthalmol. Soc. N. Z."},{"key":"10.1016\/j.ghir.2016.03.004_bb0315","first-page":"33","article-title":"Aspects of growth hormone control in diabetes","volume":"18","author":"Hyer","year":"1990","journal-title":"J. Ophthalmol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0320","first-page":"187","article-title":"Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy","volume":"120","author":"Hyer","year":"1989","journal-title":"Acta Endocrinol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0325","first-page":"61","article-title":"Failure to suppress GH secretion after 2weeks treatment with atropine or propanthelene in diabetics with proliferative retinopathy","volume":"119","author":"Hyer","year":"1988","journal-title":"Acta Endocrinol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0330","first-page":"443","article-title":"Pituitary ablation for diabetic retinopathy","volume":"34","author":"Joplin","year":"1965","journal-title":"Q. J. Med."},{"key":"10.1016\/j.ghir.2016.03.004_bb0335","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3109\/00365519009091600","article-title":"Growth hormone (GH) therapy in GH-deficient patients, the plasma factor VII-von Willebrand factor complex. and capillary fragility. A double-blind, placebo-controlled crossover study","volume":"50","author":"Jorgensen","year":"1990","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.ghir.2016.03.004_bb0340","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1001\/archopht.1990.01070050070033","article-title":"Electrophysiological changes in juvenile diabetes without retinopathy","volume":"108","author":"Juen","year":"1990","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0345","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2337\/diab.34.7.710","article-title":"Growth hormone responses to growth-hormone-releasing hormone and thyrotropin-releasing hormone in diabetic patients with and without retinopathy","volume":"34","author":"Kaneko","year":"1985","journal-title":"Diabetes"},{"key":"10.1016\/j.ghir.2016.03.004_bb0350","first-page":"766","article-title":"Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in type I (insulin-dependent) diabetes mellitus","volume":"122","author":"Kirkegaard","year":"1990","journal-title":"Acta Endocrinol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0355","first-page":"409","article-title":"When is pituitary ablation indicated as a treatment for diabetic retinopathy?","volume":"8","author":"Kohner","year":"1971","journal-title":"Acta Diabetol. Lat."},{"key":"10.1016\/j.ghir.2016.03.004_bb0360","first-page":"2380","article-title":"Retinal changes mimicking diabetic retinopathy in two nondiabetic, growth hormone-treated patients","volume":"83","author":"Koller","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"Suppl A","key":"10.1016\/j.ghir.2016.03.004_bb0365","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1016\/S1096-6374(01)80017-4","article-title":"Growth hormone receptor antagonists: discovery and potential uses","volume":"11","author":"Kopchick","year":"2001","journal-title":"Growth Hormon. IGF Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0370","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00347-003-0903-2","article-title":"Therapy of diabetic retinopathy with somatostatin analogues","volume":"101","author":"Lang","year":"2004","journal-title":"Ophthalmologe"},{"key":"10.1016\/j.ghir.2016.03.004_bb0375","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2265.2005.02402.x","article-title":"Diabetic retinopathy, nephropathy and cardiovascular disease in a patient with GH gene deletion","volume":"63","author":"Laron","year":"2005","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0380","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2337\/diab.26.8.798","article-title":"Growth hormone antiserum suppresses the growth effect of diabetic serum: studies on rabbit aortic medial cell culture","volume":"26","author":"Ledet","year":"1977","journal-title":"Diabetes"},{"key":"10.1016\/j.ghir.2016.03.004_bb0385","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0026-0495(79)90169-0","article-title":"Increased von Willebrand factor in diabetes mellitus","volume":"28","author":"Lufkin","year":"1979","journal-title":"Metabolism"},{"key":"10.1016\/j.ghir.2016.03.004_bb0390","series-title":"Symposium on the Treatment of Diabetic Retinopathy","first-page":"291","article-title":"Hypophysectomy for diabetic angiography: a controlled clinical trial","author":"Lundback","year":"1989"},{"key":"10.1016\/j.ghir.2016.03.004_bb0395","first-page":"845","article-title":"Growth hormone's role in diabetic microangiopathy","volume":"25","author":"Lundback","year":"1976","journal-title":"Diabetes"},{"key":"10.1016\/j.ghir.2016.03.004_bb0400","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.0954-6820.1970.tb08049.x","article-title":"Pituitary ablation in diabetics with severe retinopathy","volume":"188","author":"Madsen","year":"1970","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.ghir.2016.03.004_bb0405","first-page":"438","article-title":"Stabilization of severe proliferative diabetic retinopathy by long-term treatment with SMS 201-995","volume":"18","author":"Mallet","year":"1992","journal-title":"Diabete Metab."},{"key":"10.1016\/j.ghir.2016.03.004_bb0410","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ghir.2011.05.008","article-title":"Selective inner retinal dysfunction in growth hormone transgenic mice","volume":"21","author":"Martin","year":"2011","journal-title":"Growth Hormon. IGF Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0415","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygcen.2014.04.004","article-title":"Secretagogue induction of GH release in QNR\/D cells: prevention of cell death","volume":"203","author":"Martinez-Moreno","year":"2014","journal-title":"Gen. Comp. Endocrinol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0420","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s00210-004-1011-9","article-title":"Effect of somatostatin analogues on chemically induced ischaemia in the rat retina","volume":"371","author":"Mastsodimou","year":"2005","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0425","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/eye.1991.99","article-title":"Effect of a long-acting somatostatin analogue (BIM23014) on proliferative diabetic retinopathy: a pilot study","volume":"5","author":"McCombe","year":"1991","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.ghir.2016.03.004_bb0430","first-page":"101","article-title":"Characteristics of the somatotropic axis in insulin dependent diabetes mellitus","volume":"26","author":"Mercado","year":"1995","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0435","first-page":"743","article-title":"Diabetes mellitus. A perspective on management","volume":"78","author":"Merimee","year":"1991","journal-title":"J. Fla Med. Assoc."},{"key":"10.1016\/j.ghir.2016.03.004_bb0440","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJM199004053221406","article-title":"Diabetic retinopathy. A synthesis of perspectives","volume":"322","author":"Merimee","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ghir.2016.03.004_bb0445","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJM198309013090904","article-title":"Insulin-like growth factors: studies in diabetics with and without retinopathy","volume":"309","author":"Merimee","year":"1983","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ghir.2016.03.004_bb0450","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJM197806012982202","article-title":"A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes","volume":"298","author":"Merimee","year":"1978","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ghir.2016.03.004_bb0455","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2337\/diab.22.11.813","article-title":"Vascular disease in the chronic HIGH-deficient state","volume":"22","author":"Merimee","year":"1973","journal-title":"Diabetes"},{"key":"10.1016\/j.ghir.2016.03.004_bb0460","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1172\/JCI106325","article-title":"Diabetes mellitus and sexual ateliotic dwarfism: a comparative study","volume":"49","author":"Merimee","year":"1970","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ghir.2016.03.004_bb0465","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/jc.2002-022049","article-title":"Growth hormone receptor antagonists","volume":"89","author":"Muller","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2016.03.004_bb0470","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/jc.2002-022049","article-title":"Clinical review 166: growth hormone receptor antagonists","volume":"89","author":"Muller","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2016.03.004_bb0475","first-page":"69","article-title":"Growth hormone receptor antagonists: potential indications","volume":"145","author":"Muller","year":"2001","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"10.1016\/j.ghir.2016.03.004_bb0480","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1055\/s-2007-1012241","article-title":"Development of specific and non-specific somatostatin analogs","volume":"18","author":"Nakano","year":"1986","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0485","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ghir.2013.03.001","article-title":"An ocular view of the IGF-IGFBP system","volume":"23","author":"Nguyen","year":"2013","journal-title":"Growth Hormon. IGF Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0490","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2337\/diab.26.2.113","article-title":"Retinopathy and plasma groth hormone levels in idiopathic hemochromatosis with diabetes","volume":"26","author":"Passa","year":"1977","journal-title":"Diabetes"},{"key":"10.1016\/j.ghir.2016.03.004_bb0495","first-page":"67","article-title":"Deterioration of visual acuity associated with growth hormone therapy in a child with extreme short stature and high hypermetropia","volume":"67","author":"Paterson","year":"2007","journal-title":"Horm. Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0500","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.neuroscience.2011.05.029","article-title":"Growth hormone and prolactin regulate human neural stem cell regenerative activity","volume":"190","author":"Pathipati","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.ghir.2016.03.004_bb0505","first-page":"21","article-title":"Perspectives of new potential therapeutic applications of somatostatin analogs","volume":"24","author":"Pawlikowski","year":"2003","journal-title":"Neuro Endocrinol. Lett."},{"key":"10.1016\/j.ghir.2016.03.004_bb0510","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000180771","article-title":"Suppression of growth hormone and somatomedin C by long-acting somatostatin analog SMS 201-995 in type I diabetes mellitus","volume":"27","author":"Plewe","year":"1987","journal-title":"Horm. Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0515","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3109\/00365528609087446","article-title":"Somatostatin analogue SMS 201-995 in type I diabetes mellitus. Initial experience after repeated administration","volume":"119","author":"Plewe","year":"1986","journal-title":"Scand. J. Gastroenterol. Suppl."},{"key":"10.1016\/j.ghir.2016.03.004_bb0520","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11102-013-0505-1","article-title":"Evaluation of central corneal and central retinal thicknesses and intraocular pressure in acromegaly patients","volume":"17","author":"Polat","year":"2014","journal-title":"Pituitary"},{"key":"10.1016\/j.ghir.2016.03.004_bb0525","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2337\/diab.2.1.7","article-title":"The Houssay phenomenon in man: recovery from retinopathy in a case of diabetes with Simmond's disease","volume":"2","author":"Poulsen","year":"1953","journal-title":"Diabetes"},{"key":"10.1016\/j.ghir.2016.03.004_bb0530","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00417-014-2650-2","article-title":"Elevated intraocular pressure in patients with acromegaly","volume":"252","author":"Quaranta","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0535","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJM198403293101307","article-title":"Development of diabetic complications despite the absence of growth hormone in a patient with post-pancreatectomy","volume":"310","author":"Radin","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ghir.2016.03.004_bb0540","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pharmthera.2015.05.007","article-title":"Therapeutic uses of somatostatin and its analogues: current view and potential applications","volume":"152","author":"Rai","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ghir.2016.03.004_bb0545","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1210\/jcem-63-5-1071","article-title":"Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patiens studied by means of an artificial pancreas","volume":"63","author":"Rios","year":"1986","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ghir.2016.03.004_bb0550","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/157339909787314176","article-title":"Metabolic control and diabetic retinopathy","volume":"5","author":"Rodriguez-Fontal","year":"2009","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.ghir.2016.03.004_bb0555","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1073\/pnas.88.2.617","article-title":"Human growth hormone stimulates proliferation of human retinal microvascular endothelial cells in vitro","volume":"88","author":"Rymaszewski","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ghir.2016.03.004_bb0560","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygcen.2010.12.013","article-title":"Growth hormone promotes the survival of retinal cells in vivo","volume":"172","author":"Sanders","year":"2011","journal-title":"Gen. Comp. Endocrinol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0565","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ygcen.2009.06.013","article-title":"Growth hormone expression and neuroprotective activity in a quail neural retina cell line","volume":"165","author":"Sanders","year":"2010","journal-title":"Gen. Comp. Endocrinol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0570","first-page":"920","article-title":"Endogenous growth hormone in human retinal ganglion cells correlates with cell survival","volume":"15","author":"Sanders","year":"2009","journal-title":"Mol. Vis."},{"key":"10.1016\/j.ghir.2016.03.004_bb0575","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.exer.2006.06.009","article-title":"Retinal ganglion cell survival in development: mechanisms of retinal growth hormone action","volume":"86","author":"Sanders","year":"2006","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0580","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.exer.2005.03.013","article-title":"Retinal growth hormone is an anti-apoptotic factor in embryonic retinal ganglion cell differentiation","volume":"81","author":"Sanders","year":"2005","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0585","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1167\/iovs.03-0500","article-title":"Opticin binds retinal growth hormone in the embryonic vitreous","volume":"44","author":"Sanders","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.ghir.2016.03.004_bb0590","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3325\/cmj.2015.56.326","article-title":"Oxidative stress impact on growth hormone secretion in the eye","volume":"56","author":"Saric","year":"2015","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.ghir.2016.03.004_bb0595","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4103\/0019-5359.48562","article-title":"Diabetic retinopathy: a comprehensive review","volume":"62","author":"Shah","year":"2008","journal-title":"Indian J. Med. Sci."},{"key":"10.1016\/j.ghir.2016.03.004_bb0600","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1464-5491.1984.tb01924.x","article-title":"Growth hormone response to hyperinsulinaemia in insulin-dependent diabetics. Comparison of patients with and without retinopathy","volume":"1","author":"Sharp","year":"1984","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ghir.2016.03.004_bb0605","first-page":"362","article-title":"Diabetes and retinal vascular dysfunction","volume":"9","author":"Shin","year":"2014","journal-title":"J. Ophthalmic Vis. Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0610","first-page":"287","article-title":"Growth hormone suppression and nonproliferative diabetic retinopathy: a preliminary feasibility study","volume":"13","author":"Shumak","year":"1990","journal-title":"Clin. Invest. Med."},{"key":"10.1016\/j.ghir.2016.03.004_bb0615","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1042\/cs1040223","article-title":"Free insulin-like growth factor 1 in the vitreous fluid of diabetic patients with proliferative diabetic retinopathy: a case-control study","volume":"104","author":"Simo","year":"2003","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.ghir.2016.03.004_bb0620","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1126\/science.276.5319.1706","article-title":"Essential role of growth hormone in ischemia-induced retinal neovascularization","volume":"276","author":"Smith","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.ghir.2016.03.004_bb0625","first-page":"627","article-title":"Pituitary ablation for diabetic retinopathy","volume":"94","author":"Speakman","year":"1966","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.ghir.2016.03.004_bb0630","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1073\/pnas.96.4.1246","article-title":"Opposing actions of intact and N-terminal fragments of the human prolactin\/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis","volume":"96","author":"Struman","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ghir.2016.03.004_bb0635","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1210\/en.2004-1115","article-title":"Increased neurogenesis in dentate gyrus of long-lived Ames dwarf mice","volume":"146","author":"Sun","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.ghir.2016.03.004_bb0640","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1677\/joe.1.06553","article-title":"A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression. IGF-I production and body weight gain in normal mice","volume":"189","author":"Tachas","year":"2006","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ghir.2016.03.004_bb0645","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/152091599316775","article-title":"Insulin-like growth factor-I in diabetes mellitus: its physiology, metabolic effects, and potential clinical utility","volume":"2","author":"Thrailkill","year":"2000","journal-title":"Diabetes Technol. Ther."},{"key":"10.1016\/j.ghir.2016.03.004_bb0650","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.phrs.2014.10.003","article-title":"Novel therapeutic approaches for diabetic nephropathy and retinopathy","volume":"98","author":"Usuelli","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0655","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/01.aids.0000189854.06194.87","article-title":"Aberrant cortical neurogenesis in a pediatric neuroAIDS model: neurotrophic effects of growth hormone","volume":"19","author":"van Marle","year":"2005","journal-title":"AIDS"},{"key":"10.1016\/j.ghir.2016.03.004_bb0660","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.biopha.2015.08.002","article-title":"Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy","volume":"74","author":"Wan","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ghir.2016.03.004_bb0665","first-page":"549","article-title":"Growth hormone (GH), brain development and neural stem cells","volume":"9","author":"Waters","year":"2011","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.ghir.2016.03.004_bb0670","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.2174\/092986706778773086","article-title":"The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy","volume":"13","author":"Wilkinson-Berka","year":"2006","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ghir.2016.03.004_bb0675","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/gt.2011.142","article-title":"Gene therapy for retinal ganglion cell neuroprotection in glaucoma","volume":"19","author":"Wilson","year":"2012","journal-title":"Gene Ther."},{"issue":"Suppl A","key":"10.1016\/j.ghir.2016.03.004_bb0680","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/S1096-6374(01)80009-5","article-title":"Modulation of retinal endothelial cell behaviour by insulin-like growth factor I and somatostatin analogues: implications for diabetic retinopathy","volume":"11","author":"Wilson","year":"2001","journal-title":"Growth Hormon. IGF Res."},{"key":"10.1016\/j.ghir.2016.03.004_bb0685","first-page":"2969","article-title":"Sex differences in thrombosis in mice are mediated by sex-specific growth hormone secretion patterns","volume":"118","author":"Wong","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ghir.2016.03.004_bb0690","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/bmj.2.5653.346","article-title":"Serum growth hormone levels and the response of diabetic retinopathy to pituitary ablation","volume":"2","author":"Wright","year":"1969","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ghir.2016.03.004_bb0695","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.neulet.2009.05.048","article-title":"Vitreous growth hormone and visual dysfunction","volume":"460","author":"Ziaei","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ghir.2016.03.004_bb9000","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1046\/j.1445-5994.2002.00149.x","article-title":"Severe diabetic retinopathy: a rare complication of acromegaly","volume":"32","author":"Tran","year":"2002","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.ghir.2016.03.004_bb9005","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12020-013-9904-3","article-title":"The metabolic effects of growth hormone in adipose tissue","volume":"44","author":"Chaves","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.ghir.2016.03.004_bb9010","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1172\/JCI19478","article-title":"Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease","author":"Ruberte","year":"2004","journal-title":"J. Clin. Invest."}],"container-title":["Growth Hormone & IGF Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637416300132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096637416300132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:49:43Z","timestamp":1761086983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096637416300132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":142,"alternative-id":["S1096637416300132"],"URL":"https:\/\/doi.org\/10.1016\/j.ghir.2016.03.004","relation":{},"ISSN":["1096-6374"],"issn-type":[{"value":"1096-6374","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Growth hormone and ocular dysfunction: Endocrine, paracrine or autocrine etiologies?","name":"articletitle","label":"Article Title"},{"value":"Growth Hormone & IGF Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ghir.2016.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}